3SBio Stock

3SBio EBIT

The EBIT of 3SBio (1530.HK) as of Aug 19, 2026 is 12.26 B CNY. In the previous year, EBIT was 3.04 B CNY — a change of 303.76% (higher).

EBIT

12.26 BCNY

YoY

303.76%

Last updated:

In 2026, 3SBio's EBIT was 12.26 B CNY, a 303.76% increase from the 3.04 B CNY EBIT recorded in the previous year.

The 3SBio EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B CNY)
Date
EBIT (B CNY)
Jan 1, 2021
2.12 base
Jan 1, 2022
2.41 base
Jan 1, 2023
2.86 base
Jan 1, 2024
3.04 base
Jan 1, 2025
12.26 base
Jan 1, 2026 (e)
3.66 base
Jan 1, 2027 (e)
3.75 base
Jan 1, 2028 (e)
4.24 base
YEAREBIT (B CNY)
2028 est 4.24
2027 est 3.75
2026 est 3.66
2025 12.26
2024 3.04
2023 2.86
2022 2.41
2021 2.12
2020 1.70
2019 1.55
2018 1.42
2017 1.34
2016 1.06
2015 0.56
2014 0.44
2013 0.32
2012 0.15
2011 0.14
2010 0.10
2009 0.10
2008 0.06
2007 0.06
2006 0.04
Access this data via the Eulerpool API

3SBio Revenue

3SBio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
7.42 B CNY
2.12 B CNY
1.92 B CNY
Jan 1, 2022
7.97 B CNY
2.41 B CNY
2.23 B CNY
Jan 1, 2023
9.08 B CNY
2.86 B CNY
1.80 B CNY
Jan 1, 2024
10.59 B CNY
3.04 B CNY
2.43 B CNY
Jan 1, 2025
20.57 B CNY
12.26 B CNY
9.86 B CNY
Jan 1, 2026 (e)
11.75 B CNY
3.66 B CNY
2.69 B CNY
Jan 1, 2027 (e)
12.13 B CNY
3.75 B CNY
3.24 B CNY
Jan 1, 2028 (e)
11.71 B CNY
4.24 B CNY
2.93 B CNY

3SBio Margins

3SBio stock margins

The 3SBio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 3SBio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 3SBio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
82.67 %
28.62 %
25.87 %
Jan 1, 2022
82.69 %
30.17 %
27.93 %
Jan 1, 2023
84.98 %
31.45 %
19.82 %
Jan 1, 2024
85.95 %
28.67 %
22.95 %
Jan 1, 2025
92.38 %
59.59 %
47.93 %
Jan 1, 2026 (e)
92.38 %
31.14 %
22.86 %
Jan 1, 2027 (e)
92.38 %
30.94 %
26.76 %
Jan 1, 2028 (e)
92.38 %
36.20 %
24.98 %

3SBio Stock analysis

What does 3SBio do? 3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing 3SBio's EBIT

3SBio's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of 3SBio's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

3SBio's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in 3SBio’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about 3SBio stock

EBIT of 3SBio is 12.26 B CNY in 2026.

EBIT of 3SBio changed from 3.04 B CNY to 12.26 B CNY, representing a 303.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT 3SBio since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's 3SBio historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — 3SBio

All Key Metrics — 3SBio